Mortality among clients seeking treatment for buprenorphine abuse in Finland

Drug and Alcohol Dependence

Volumn 133, Issue 2, 2013, Pages 391-397

  Uosukainen, Hanna ^a   Kauhanen, Jussi ^a   Bell, J Simon ^a,b,c   Ronkainen, Kimmo ^a   Tiihonen, Jari ^a,d,e   Föhr, Jaana ^f   Onyeka, Ifeoma N ^a   Korhonen, Maarit J ^a,g  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Helsinki Deaconess Institute   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

Buprenorphine; Follow up; Mortality; Treatment seeking

Indexed keywords

BUPRENORPHINE;

ACCIDENTAL DEATH; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DRUG ABUSE; DRUG FATALITY; FEMALE; FINLAND; FOLLOW UP; HELP SEEKING BEHAVIOR; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; SUICIDE; SURVIVAL RATE;

BUPRENORPHINE; FOLLOW-UP; MORTALITY; TREATMENT SEEKING;

ACCIDENTS; ADULT; AGE FACTORS; BUPRENORPHINE; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FINLAND; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; SEX FACTORS; SUICIDE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84887019528     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.06.022     Document Type: Article

References (53)

1. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. Am. J. Addict. 2004, 13(Suppl. 1):S17-S28.
2. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001, 285:45.
3. Bargagli A.M., Hickman M., Davoli M., Perucci C.A., Schifano P., Buster M., Brugal T., Vicente J., COSMO European Group Drug-related mortality and its impact on adult mortality in eight European countries. Eur. J. Public Health 2006, 16:198-202.
4. Bargagli A.M., Sperati A., Davoli M., Forastiere F., Perucci C.A. Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97. Addiction 2001, 96:1455-1463.
5. Bartu A., Freeman N.C., Gawthorne G.S., Codde J.P., Holman C.D. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction 2004, 99:53-60.
6. Bell J.R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009, 104:73-77.
7. Bell J., Trinh L., Butler B., Randall D., Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009, 104:1193-1200.
8. Bjornaas M.A., Bekken A.S., Ojlert A., Haldorsen T., Jacobsen D., Rostrup M., Ekeberg O. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry 2008, 8:8.
9. Cerdá M., Ransome Y., Keyes K.M., Koenen K.C., Tracy M., Tardiff K.J., Vlahov D., Galea S. Prescription opioid mortality trends in New York City, 1990-2006: examining the emergence of an epidemic. Drug Alcohol Depend. 2013, (E-pub ahead of print).
10. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
11. Copeland L., Budd J., Robertson J.R., Elton R.A. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch. Intern. Med. 2004, 164:1214-1220.
12. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010, 341:c5475.
13. Darke S., Mills K.L., Ross J., Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend. 2011, 115:190-195.
14. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
15. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012, 379:55-70.
16. Degenhardt L., Larance B., Mathers B., Azim T., Kamarulzaman A., Mattick R., Panda S., Toufik A., Tyndall M., Wiessing L., Wodak A. Benefits and Risks of Pharmaceutical Opioids: Essential Treatment and Diverted Medication. A Global Review of Availability, Extra-Medical Use, Injection and the Association with HIV 2008, Available from, (accessed 18.12.12). http://www.unodc.org/documents/hiv-aids/publications/Benefits_and_risks_of_pharmaceutical_opioids.pdf.
17. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009, 105:9-15.
18. Degenhardt L., Roxburgh A., Barker B. Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. J. Clin. Forensic Med. 2005, 12:187-195.
19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Standard Protocol Version 3.2 for the EU Member States to Collect Data and Report Figures for the Key Indicator Drug-related Deaths. EMCDDA project CT.02.P1.05 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Mortality Related to Drug Use in Europe: Public Health Implications. Selected Issue 2011 2011, Publications Office of the European Union, Luxembourg.
21. Forsell M., Virtanen A., Jääskeläinen M., Alho H., Partanen A. Drug situation in Finland 2010. National Report to the EMCDDA by the Finnish National Focal Point 2010, National Institute for Health and Welfare (THL), Report 39/2010, Helsinki.
22. Gibson A., Degenhardt L., Mattick R.P., Ali R., White J., O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008, 103:462-468.
23. Gossop M., Stewart D., Treacy S., Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002, 97:39-47.
24. Gueye P.N., Megarbane B., Borron S.W., Adnet F., Galliot-Guilley M., Ricordel I., Tourneau J., Goldgran-Toledano D., Baud F.J. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction 2002, 97:1295-1304.
25. Häkkinen M., Launiainen T., Vuori E., Ojanperä I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur. J. Clin. Pharmacol. 2012, 68:301-309.
26. Hernandez S.H., Nelson L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther. 2010, 88:307-317.
27. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012, 120:190-195.
28. Jönsson A.K., Holmgren P., Druid H., Ahlner J. Cause of death and drug use pattern in deceased drug addicts in Sweden, 2002-2003. Forensic Sci. Int. 2007, 169:101-107.
29. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 2001, 121:65-69.
30. Kintz P. A new series of 13 buprenorphine-related deaths. Clin. Biochem. 2002, 35:513-516.
31. Kivelä P.S., Krol A., Salminen M.O., Ristola M.A. Determinants of late HIV diagnosis among different transmission groups in Finland from 1985 to 2005. HIV Med. 2010, 11:360-367.
32. Lai S.H., Yao Y.J., Lo D.S. A survey of buprenorphine related deaths in Singapore. Forensic Sci. Int. 2006, 162:80-86.
33. Ling W., Mooney L., Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 2011, 30:300-305.
34. Megarbane B., Buisine A., Jacobs F., Resiere D., Chevillard L., Vicaut E., Baud F.J. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J. Subst. Abuse Treat. 2010, 38:403-407.
35. Merrall E.L., Bird S.M., Hutchinson S.J. Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. Int. J. Drug Policy 2012, 23:24-32.
36. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102:616-622.
37. Nyhlen A., Fridell M., Hesse M., Krantz P. Causes of premature mortality in Swedish drug abusers: a prospective longitudinal study 1970-2006. J. Forensic Leg. Med. 2011, 18:66-72.
38. Ødegård E., Amundsen E.J., Kielland K.B. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers-a competing risk approach. Drug Alcohol Depend. 2007, 89:176-182.
39. Official Statistics of Finland (OSF) Quality description. Causes of Death, Helsinki 2011, Available from, (accessed 11.02.13). http://www.stat.fi/til/ksyyt/2011/ksyyt_2011_2012-12-21_laa_001_en.html.
40. Official Statistics of Finland (OSF) Causes of Death, Helsinki 2012, Available from, (accessed 30.11.12). http://www.stat.fi/til/ksyyt/index_en.
41. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanidze M., Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine?. Eur. Addict. Res. 2010, 16:1-8.
42. Pelissier-Alicot A.L., Sastre C., Baillif-Couniou V., Gaulier J.M., Kintz P., Kuhlmann E., Perich P., Bartoli C., Piercecchi-Marti M.D., Leonetti G. Buprenorphine-related deaths: unusual forensic situations. Int. J. Legal Med. 2010, 124:647-651.
43. Romelsjö A., Engdahl B., Stenbacka M., Fugelstad A., Davstad I., Leifman A., Thiblin I. Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity?. Addiction 2010, 105:1625-1632.
44. Schifano F., Corkery J., Gilvarry E., Deluca P., Oyefeso A., Ghodse A.H. Buprenorphine mortality, seizures and prescription data in the UK, 1980-2002. Hum. Psychopharmacol. 2005, 20:343-348.
45. Selden T., Ahlner J., Druid H., Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci. Int. 2012, 220:284-290.
46. Simonsen K.W., Normann P.T., Ceder G., Vuori E., Thordardottir S., Thelander G., Hansen A.C., Teige B., Rollmann D. Fatal poisoning in drug addicts in the Nordic countries in 2007. Forensic Sci. Int. 2011, 207:170-176.
47. Soyka M., Trader A., Klotsche J., Backmund M., Buhringer G., Rehm J., Wittchen H.U. Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study. J. Clin. Psychopharmacol. 2011, 31:678-680.
48. Stenbacka M., Leifman A., Romelsjö A. Mortality and cause of death among 1705 illicit drug users: a 37 year follow up. Drug Alcohol Rev. 2010, 29:21-27.
49. Uosukainen H., Kauhanen J., Voutilainen S., Föhr J., Paasolainen M., Tiihonen J., Laitinen K., Onyeka I.N., Bell J.S. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend. 2013, 127:207-214.
50. Vandenbroucke J.P. A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio. Am. J. Epidemiol. 1982, 115:303-304.
51. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 1994, 55:569-580.
52. Winslow M., Ng W.L., Mythily S., Song G., Yiong H.C. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore. Ann. Acad. Med. Singapore 2006, 35:451-456.
53. World Health Organization (WHO) ICD-10 International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Instruction Manual 2010, vol. 2.